WIPO General Assembly 2017: KEI statement on the Standing Committee on the Law of Patents (SCP)

On Wednesday, 4 October 2017, Knowledge Ecology International (KEI) delivered the following statement at the WIPO General Assembly during discussions on the Report of the Standing Committee on the Law of Patents (SCP).

WIPO General Assembly 2017 – Statement of KEI on the Report on the Standing Committee on the Law of Patents (SCP)

4 October 2017

Agenda item: 14. Report on the Standing Committee on the Law of Patents (SCP)

Continue Reading

Kite Pharma Press Releases & News Stories Related to Relationship with National Cancer Institute

Kite Pharma is a California-based biopharmaceutical company working on various types of cell therapies for the treatment of cancer, in a bid to become the first pharmaceutical firm to gain successful FDA approval for this new class of cancer treatment.

Kite closely collaborates with the National Cancer Institute, which conducted significant early research into the forms of cell therapies that Kite is seeking to commercialize. NCI conducts clinical trials under Cooperative Research and Development Agreements (CRADAs) with Kite, and additionally has granted exclusive licenses on over a dozen patents to Kite on the same technologies.
Continue Reading

Intervention of the South Centre at EB134 expressing solidarity with the Republic of South Africa

On Thursday, 23 January 2014, the South Centre delivered the following statement at the 134th session of the World Health Organization’s Executive Board under agenda item 9.7, access to essential medicines, expressing solidarity with the Government of the Republic of South Africa following the Pharmagate exposé.

GRACIAS SENORA PRESIDENTA POR DARNOS LA PALABRA.

Continue Reading

Uncategorized

PAF v AbbVie excessive pricing case the Netherlands

On 14 May 2024, the Pharmaceutical Accountability Foundation (PAF) had their first hearing in their case against Abbvie at the Amsterdam District Court. The case concerns Abbvie’s pricing practices for its blockbuster drug Humira (adalimumab), one of the world’s best-selling… Continue Reading

KEI Comments on NIH License to McSAF for Antibody-Drug Conjugates for Cancer

Knowledge Ecology International (KEI) offered the following comments to the National Institutes of Health (NIH) concerning the “Prospective Grant of an Exclusive Patent License: Antibody-Drug Conjugates (ADCs) for Targeting CD56-Positive Tumors” (89 FR 40495) to McSAF Inside Oncology SAS (McSAF).… Continue Reading

Letter to Anne Yu, Director for Global Pandemic Preparedness, NSC, on negotiations for WHO pandemic agreement

This was sent via email today. Jamie ————— May 1, 2024 Anne Yu Director for Global Pandemic Preparedness Development, Global Health and Humanitarian Response, National Security Council Staff, Executive Office of the President Dear Anne Yu, I’m guessing you are… Continue Reading